entertainment -WSS

entertainment

author：entertainment 2025-09-29 21:25:28 - browse：267

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in the second quarter compared to the year-ago period, as the biotech prepares for a key meeting with the Food and Drug Administration in September.

Net product sales in the quarter were $306 million, led by Amvuttra, the company’s RNAi treatment for hereditary ATTR, with sales of $132 million, exceeding Wall Street forecasts. Sales of Onpattro, its older medicine for hereditary ATTR, were $91 million, slightly less than expectations.

The FDA has scheduled a meeting of outside experts on Sept. 13 to discuss the company’s application to expand the indication for Onpattro to include ATTR-CM, a related condition that affects the heart. The FDA decision is due by Oct. 8. An expansion would open a much larger market for the drug than its current approval, which largely targets nerve-related damage.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Biotech incubator Curie.Bio graduates its first startup

hotspot

WSS

Trump indictment: Who are the 'co

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

UCSF medical school apologizes for unethical prisoner experiments

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

Senate panel clears PBM, hopsital reforms

Vertex non

hotspot

entertainment

focus

As demand for Covid shots wanes, Moderna seeks its next success

Abortion clinic in Cancun will cater to Americans

Virginia high school admissions case could be legal follow

Just how powerful is the placebo effect?

How one medical school became remarkably diverse

Physician groups backed by private equity giant lobby on mergers

ChatGPT in medicine: STAT answers readers' burning questions

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

United colonoscopy coverage change 'may cost lives,' doctors say

STAT Executive Editor Rick Berke on STAT's 8th birthday

hotspot

FDA approves potent Eli Lilly obesity drug, Zepbound

FDA approves Recor Medical high blood pressure device

STAT Executive Editor Rick Berke on STAT's 8th birthday

Mitch McConnell episode has important public health takeaway

Breakthrough Alzheimer’s drugs are inaccessible in rural states

Excited delirium, Elijah McClain, and emergency physicians

focus

hotspot

hotspot

leisure time